Form 4: Alnylam CCO Sells Shares for Tax Obligations

Alnylam Pharmaceuticals' Chief Commercial Officer, Tolga Tanguler, sold 2,309 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Tolga Tanguler, Executive Vice President and Chief Commercial Officer of Alnylam Pharmaceuticals, Inc. (ALNY), reported transactions on March 4, 2026.
• The transactions involved the disposition of 2,309 shares of common stock.
• These shares were automatically sold by the company on behalf of Mr. Tanguler to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.
• The sales occurred at weighted average prices ranging from $319.03 to $325.67 per share.
• Following these transactions, Mr. Tanguler beneficially owns 34,297 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was non-discretionary and solely for tax withholding purposes related to vested equity compensation, which is a standard practice.

Positives

• The underlying event for the sale was the vesting of restricted stock units, which represents a form of equity compensation for the executive.

Negatives

• The direct beneficial ownership of common stock by the Chief Commercial Officer decreased by 2,309 shares.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• Shares were automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that routine 'sell-to-cover' transactions, like the one reported, are a common occurrence for executives receiving equity compensation. These sales are typically non-discretionary and are executed to satisfy tax liabilities upon the vesting of restricted stock units, rather than reflecting a change in management's sentiment about the company's future prospects or operational performance.

Stakeholder Impact

• Shareholders: The impact on shareholders is generally neutral as this is a routine, non-discretionary transaction for tax purposes, not an indication of a change in the executive's confidence in the company.

Key Dates

Recommendation

The reported transaction is a standard 'sell-to-cover' for tax obligations upon RSU vesting, not a discretionary sale. It provides no new information to alter an investment thesis for Alnylam Pharmaceuticals, thus a 'hold' recommendation is appropriate.

Keywords

Alnylam Pharmaceuticals, ALNY, Insider Transaction, Form 4, Executive Compensation, Restricted Stock Units, Tax Withholding, Stock Sale